<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We discuss different strategies for the treatment of invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> (IFI) in high risk patients with a focus on patients experiencing profound and prolonged <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, comprising those with <z:hpo ids='HP_0011009'>acute</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) during remission induction chemotherapy and on patients undergoing allogeneic haematopoietic stem cell transplantation (SCT) </plain></SENT>
<SENT sid="1" pm="."><plain>Among these patients, invasive <z:e sem="disease" ids="C0004030" disease_type="Disease or Syndrome" abbrv="">aspergillosis</z:e> (IA) is the most frequently observed form of IFI, as opposed to high risk intensive care unit (ICU) patients in whom an increased incidence of <z:e sem="disease" ids="C1609535" disease_type="Disease or Syndrome" abbrv="">invasive candidiasis</z:e> (IC) can be observed </plain></SENT>
<SENT sid="2" pm="."><plain>In both groups, initiation of early treatment has a profound impact on mortality rates, but adequate diagnostic tools are lacking </plain></SENT>
<SENT sid="3" pm="."><plain>These circumstances have led to the parallel use of different treatment strategies, e.g. prophylaxis, empiric, pre-emptive and targeted treatment of IFI </plain></SENT>
<SENT sid="4" pm="."><plain>The optimum treatment strategies for these severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> are a matter of extensive research and discussion </plain></SENT>
<SENT sid="5" pm="."><plain>A review of major clinical trials on the issue reveals that comparisons between different treatment strategies cannot be made </plain></SENT>
<SENT sid="6" pm="."><plain>Considering the complexity of the issue, we advocate an eclectic treatment approach that reduces morbidity and mortality from IFI without compromising tolerability </plain></SENT>
<SENT sid="7" pm="."><plain>In allogeneic HSCT recipients, patients receiving induction chemotherapy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and those under immunosuppressive medication for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft vs. host disease</z:e> after allogeneic HSCT, we recommend prophylaxis with posaconazole </plain></SENT>
<SENT sid="8" pm="."><plain>For empiric treatment of persistently febrile neutropenic patients, we opt for caspofungin as first and <z:chebi fb="0" ids="2682">liposomal amphotericin B</z:chebi> <z:chebi fb="0" ids="23614">deoxycholate</z:chebi> (L-AmB) as second line choice </plain></SENT>
<SENT sid="9" pm="."><plain>If the diagnosis of IA can be established, <z:chebi fb="0" ids="10023">voriconazole</z:chebi> should be favoured over the alternative, <z:chebi fb="0" ids="2682">liposomal amphotericin B</z:chebi> (L-AmB) </plain></SENT>
<SENT sid="10" pm="."><plain>While high risk ICU patients benefit from <z:chebi fb="2" ids="46081">fluconazole</z:chebi> prophylaxis for IC, the choice of an optimal agent for targeted therapy depends largely on the neutrophil count </plain></SENT>
<SENT sid="11" pm="."><plain>In non-neutropenic patients, we recommend an echinocandin as the first line treatment option </plain></SENT>
<SENT sid="12" pm="."><plain>Patients with susceptible Candida spp. may be switched to <z:chebi fb="2" ids="46081">fluconazole</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain>Caspofungin or micafungin might be preferred to anidulafungin in the neutropenic patient </plain></SENT>
<SENT sid="14" pm="."><plain>L-AmB is a valuable second line treatment option for both groups of patients </plain></SENT>
</text></document>